SAMHD1 is active in cycling cells permissive to HIV-1 infection

Antiviral Res. 2017 Jun:142:123-135. doi: 10.1016/j.antiviral.2017.03.019. Epub 2017 Mar 28.

Abstract

SAMHD1 is a triphosphohydrolase that restricts HIV-1 by limiting the intracellular dNTP pool required for reverse transcription. Although SAMHD1 is expressed and active/unphosphorylated in most cell lines, its restriction activity is thought to be relevant only in non-cycling cells. However, an in depth evaluation of SAMHD1 function and relevance in cycling cells is required. Here, we show that SAMHD1-induced degradation by HIV-2 Vpx affects the dNTP pool and HIV-1 replication capacity in the presence of the 3'-azido-3'-deoxythymidine (AZT) in cycling cells. Similarly, in SAMHD1 knockout cells, HIV-1 showed increased replicative capacity in the presence of nucleoside inhibitors, especially AZT, that was reverted by re-expression of wild type SAMHD1. Sensitivity to non-nucleoside inhibitors (nevirapine and efavirenz) or the integrase inhibitor raltegravir was not affected by SAMHD1. Combination of three mutations (S18A, T21A, T25A) significantly prevented SAMHD1 phosphorylation but did not significantly affect HIV-1 replication in the presence of AZT. Our results demonstrate that SAMHD1 is active in HIV-1 permissive cells, does not modify susceptibility to HIV-1 infection but strongly affects sensitivity to nucleoside inhibitors.

Keywords: CRISPR; Genome editing; SAMHD1; dNTPase activity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Clustered Regularly Interspaced Short Palindromic Repeats
  • DNA Replication / drug effects
  • Gene Editing
  • Gene Expression
  • Gene Knockdown Techniques
  • HEK293 Cells
  • HIV Infections / metabolism
  • HIV-1 / drug effects*
  • HIV-1 / pathogenicity
  • HIV-2 / drug effects
  • Host-Pathogen Interactions
  • Humans
  • Phosphorylation
  • Reverse Transcription / drug effects
  • SAM Domain and HD Domain-Containing Protein 1 / genetics
  • SAM Domain and HD Domain-Containing Protein 1 / metabolism
  • SAM Domain and HD Domain-Containing Protein 1 / pharmacology*
  • Viral Regulatory and Accessory Proteins / drug effects
  • Virus Replication / drug effects*
  • Zidovudine / pharmacology

Substances

  • VPX protein, Human immunodeficiency virus 2
  • Viral Regulatory and Accessory Proteins
  • Zidovudine
  • SAM Domain and HD Domain-Containing Protein 1
  • SAMHD1 protein, human